[1]唐奇远,吴晓娟,赖晓娟,等.Peg-IFNa-2b单药与联合NAs治疗HBeAg阳性慢乙肝初治患者的疗效比较[J].医学信息,2022,35(08):115-117.[doi:10.3969/j.issn.1006-1959.2022.08.028]
　TANG Qi-yuan,WU Xiao-juan,LAI Xiao-juan,et al.Comparison of the Efficacy on Peg-IFNa-2b Monotherapy and NAs Combined Therapy in Patients with HBeAg Positive Chronic Hepatitis B[J].Medical Information,2022,35(08):115-117.[doi:10.3969/j.issn.1006-1959.2022.08.028]
点击复制

Peg-IFNa-2b单药与联合NAs治疗HBeAg阳性慢乙肝初治患者的疗效比较()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年08期
页码:
115-117
栏目:
论著
出版日期:
2022-04-15

文章信息/Info

Title:
Comparison of the Efficacy on Peg-IFNa-2b Monotherapy and NAs Combined Therapy in Patients with HBeAg Positive Chronic Hepatitis B
文章编号:
1006-1959（2022）08-0115-03
作者:
唐奇远; 吴晓娟; 赖晓娟; 等
（深圳市第三人民医院肝病二科，广东 深圳 518000）
Author(s):
TANG Qi-yuan; WU Xiao-juan; LAI Xiao-juan; et al.
(The Second Department of Liver Diseases,Shenzhen Third People’s Hospital,Shenzhen 518000,Guangdong,China)
关键词:
慢性乙型肝炎; 干扰素; 核苷（酸）类似物
Keywords:
ChronichepatitisB; Interferon; Nucleoside analogues
分类号:
R512.62
DOI:
10.3969/j.issn.1006-1959.2022.08.028
文献标志码:
A
摘要:
目的 比较聚乙二醇干扰素α-2b（Peg-IFNa-2b）单药治疗与联合核苷（酸）类药物（NAs）治疗HBeAg阳性初治慢性乙型肝炎（CHB）的疗效差异。方法 收集2017年1月-2020年12月就诊于深圳市第三人民医院的HBeAg阳性CHB初治患者共69例，根据治疗方案分为单药治疗组（30例）和联合治疗组（39例），单药治疗组单用Peg-IFNa-2b治疗，联合治疗组以Peg-IFNa-2b联合NAs治疗，比较两组治疗12、24、48周的HBV DNA转阴率、HBeAg转阴率、HBsAg下降值、ALT复常率、eGFR下降等情况差异。结果 联合治疗组24、48周的HBV DNA转阴率高于单药治疗组，差异有统计学意义（P＜0.05）；两组HBeAg转阴率、HBsAg下降值、ALT复常率、eGFR变化比较，差异无统计学意义（P＞0.05）。结论 与单用Peg-IFNa-2b相比，联合核苷（酸）类治疗可提高HBeAg阳性慢性乙型肝炎患者病毒学应答率。
Abstract:
Objective To compare the efficacy of pegylated interferon α-2b (Peg-IFNa-2b) alone and combined with nucleoside analogues drugs (NAs) in the treatment of HBeAg-positive chronic hepatitis B (CHB).Methods A total of 69 patients with HBeAg-positive CHB who were treated in Shenzhen Third People’s Hospital from January 2017 to December 2020 were enrolled. According to the treatment plan, they were divided into single drug treatment group (30 cases) and combined treatment group (39 cases). The single drug treatment group was treated with Peg-IFNa-2b alone, and the combined treatment group was treated with Peg-IFNa-2b combined with NAs. The negative conversion rate of HBVDNA, negative conversion rate of HBeAg, decline of HBsAg, normalization rate of ALT and decline of eGFR were compared between the two groups at 12, 24 and 48 weeks of treatment.Results The negative conversion rate of HBVDNA in the combined treatment group at 24 and 48 weeks was higher than that in the single drug treatment group, and the difference was statistically significant (P<0.05); there was no significant difference in HBeAg negative conversion rate, HBsAg decline, ALT normalization rate and eGFR between the two groups (P>0.05).Conclusion Compared with Peg-IFNa-2b alone, combined nucleoside (acid) therapy can improve the virological response rate of HBeAg positive chronic hepatitis B patients.

参考文献/References:

[1]European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J].J Hepatol,2017,67(2):370-398.[2]中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南（2019年版）[J].中华肝脏病杂志,2019(12):938-961.[3]Spyrou E,Smith CI,Ghany MG.Hepatitis B: Current Status of Therapy and Future Therapies[J].Gastroenterol Clin North Am,2020,49(2):215-238.[4]Tao Y,Wu D,Zhou L,et al.Present and Future Therapies for Chronic Hepatitis B[J].Adv Exp Med Biol,2020(1179):137-186.[5]Loomba R,Liang TJ.Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies:Current Concepts,Management Strategies,and Future Directions[J].Gastroenterology,2017,152(6):1297-1309.[6]Higashi-Kuwata N,Hayashi S,Kumamoto H,et al.Identification of a novel long-acting 4’-modified nucleoside reverse transcriptase inhibitor against HBV[J].J Hepatol,2021,74(5):1075-1086.[7]Liu Y,Liu H,Hu Z,et al.Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination[J].Hepatology,2020,71(2):463-476.[8]Mu D,Yuan FC,Chen Y,et al.Baseline value of intrahepatic HBV DNA over cccDNA predicts patient’s response to interferon therapy[J].Sci Rep,2017,7(1):5937.[9]Cao W,Li M,Zhang L,et al.The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy[J].Biomed Res Int,2021(2021):2178143.[10]Lin S,Fu Y,Wu W,et al.The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone[J].Int J Med Sci,2020,17(10):1458-1463.[11]Marcellin P,Ahn SH,Ma X,et al.Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B[J].Gastroenterology,2016,150(1):134-144.[12]Tangkijvanich P,Chittmittraprap S,Poovorawan K,et al.A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response[J].J Viral Hepat,2016,23(6):427-438.

相似文献/References:

[1]尹静华.核黄素磷酸钠联合干扰素治疗小儿疱疹性咽峡炎的 疗效观察[J].医学信息,2018,31(10):138.[doi:10.3969/j.issn.1006-1959.2018.10.046]
　YIN Jing-hua.Therapeutic Effect of Riboflavin Sodium Phosphate Combined with Interferon on Pediatric Herpangina[J].Medical Information,2018,31(08):138.[doi:10.3969/j.issn.1006-1959.2018.10.046]
[2]林晓岚,郑丽花,陈苑莉,等.微信随访对慢性乙型肝炎患者抗病毒治疗效果和 生活质量的影响研究[J].医学信息,2018,31(10):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
　LIN Xiao-lan,ZHENG Li-hua,CHEN Yuan-li,et al.Effect of WeChat Follow-up on Antiviral Treatment and Quality of Life in Patients with Chronic Hepatitis B[J].Medical Information,2018,31(08):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
[3]林晓岚,陈苑莉.慢性乙型肝炎患者治疗依从性及其对生活质量的影响[J].医学信息,2018,31(13):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
　LIN Xiao-lan,CHEN Yuan-li.Treatment Compliance of Patients with Chronic Hepatitis B and its Influence on Quality of Life[J].Medical Information,2018,31(08):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
[4]吴 刚,吴锦瑜.HBeAg阴性慢性乙型肝炎患者血清25-羟基维生素D3的检测及临床意义[J].医学信息,2018,31(19):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
　WU Gang,WU Jin-yu.Detection and Clinical Significance of Serum 25-hydroxyvitamin D3 in Patients with HBeAg-negative Chronic Hepatitis B[J].Medical Information,2018,31(08):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
[5]叶向荣.恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价[J].医学信息,2018,31(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
　YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Medical Information,2018,31(08):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
[6]傅 蕊,李士欣,周国强,等.床旁超声预测慢性乙型肝炎患者胃镜检查围麻醉期误吸风险的临床价值[J].医学信息,2019,32(08):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
　FU Rui,LI Shi-xin,ZHOU Guo-qiang,et al.Clinical Value of Bedside Ultrasound in Predicting the Risk of Aspiration during Perioperative Anesthesia in Patients with Chronic Hepatitis B[J].Medical Information,2019,32(08):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
[7]张媛媛,徐 曼.慢性乙型肝炎患者e抗原消失的临床特点[J].医学信息,2019,32(10):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
　ZHANG Yuan-yuan,XU Man.Clinical Features of e Antigen Disappearance in Patients with Chronic Hepatitis B[J].Medical Information,2019,32(08):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
[8]罗 丹,梁惠卿,吴耀南.吴耀南教授基于“伏邪”理论治疗慢性乙肝的验案举隅[J].医学信息,2019,32(19):158.[doi:10.3969/j.issn.1006-1959.2019.19.052]
[9]周腾腾,郑 莹,梁恵卿,等.蛋白质组学在慢性乙型肝炎常见中医证型中的研究[J].医学信息,2019,32(20):30.[doi:10.3969/j.issn.1006-1959.2019.20.009]
　ZHOU Teng-teng,ZHENG Ying,LIANG Hui-qing,et al.Study on Proteomics in Common TCM Syndromes of Chronic Hepatitis B[J].Medical Information,2019,32(08):30.[doi:10.3969/j.issn.1006-1959.2019.20.009]
[10]陈 欢,李秀惠.急、慢性乙型肝炎及乙肝肝硬化患者 肝功能及血脂水平分析[J].医学信息,2019,32(12):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
　CHEN Huan,LI Xiu-hui.Analysis of Liver Function and Blood Lipid Levels in Patients with Acute, Chronic Hepatitis B and Hepatitis B Cirrhosis[J].Medical Information,2019,32(08):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
[11]汪晓凤,邵和军.慢性乙型肝炎抗病毒治疗进展[J].医学信息,2019,32(04):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
　WANG Xiao-feng,SHAO He-jun.Progress in Antiviral Therapy for Chronic Hepatitis B[J].Medical Information,2019,32(08):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]

更新日期/Last Update: 1900-01-01